Devonian Health Group Inc. (CVE:GSD – Get Free Report)’s share price traded down 23.5% during mid-day trading on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during mid-day trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Stock Down 23.5%
The firm’s fifty day simple moving average is C$0.16 and its 200 day simple moving average is C$0.17. The company has a market cap of C$19.27 million, a price-to-earnings ratio of -4.64 and a beta of 0.67. The company has a current ratio of 1.07, a quick ratio of 7.82 and a debt-to-equity ratio of 16.36.
Devonian Health Group Company Profile
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
Featured Stories
- Five stocks we like better than Devonian Health Group
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- How to Buy Cheap Stocks Step by Step
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- A Deeper Look at Bid-Ask Spreads
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
